

Testicular (Germ Cell) Cancer Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op
__1st Line __2nd Line __3rd Line __3rd Line+ __Maint

ECOG Performance Status: _____ ICD-10 Code: _____

Biomarkers/Characteristics: (select all that apply)

Platinum-refractory or resistant? __Yes __No __Not Reported

Seminoma | Stage IS-III A | Primary Therapy

BEP: bleomycin, etoposide (Toposar), and cisplatin

EP: etoposide (Toposar) and cisplatin

Seminoma | Stage IIIB-C | Good and Intermediate Risk | Metastatic Disease

BEP: bleomycin, etoposide (Toposar), and cisplatin*

EP: etoposide and cisplatin†

Nonseminoma | Stage IS-III A | Primary Therapy

BEP: bleomycin, etoposide (Toposar), and cisplatin

EP: etoposide (Toposar) and cisplatin

Nonseminoma | Stage IIIB-C | Primary Therapy

BEP: bleomycin, etoposide (Toposar), and cisplatin

Nonseminoma | Adjuvant Therapy after RPLND‡

EP: etoposide (Toposar) and cisplatin

* BEP is typically given for 3 cycles in good risk seminoma, and 4 cycles in intermediate risk

† Limited to patients with good risk seminoma

‡ RPLND: Retroperitoneal lymph node dissection

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue
South Tower - Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 5/10/2022 | Effective date: 9/27/2021

Appropriate.Safe.Affordable
© 2022 AIM Specialty Health
9022-0921